Merrion Pharmaceuticals Selected to Present at UBS 2010 Global Life Sciences Conference in New York

Merrion Pharmaceuticals Selected to Present at UBS 2010 Global Life Sciences Conference in New York

DUBLIN, Ireland, September 20, 2010 - Merrion Pharmaceuticals plc (MERR: ESM) today announced its participation, by invitation, in the prestigious UBS Global Life Sciences Conference in New York. The company will be presenting at 2:30PM EDT on Tuesday, September 21, 2010 at the Grand Hyatt Hotel, Park Avenue, New York.

The 2010 Global Life Sciences Conference provides clients with a unique perspective on the life sciences industry and will feature representatives from approximately 270 companies in the following life sciences sectors: Biotechnology, Life Sciences Tools, Medical Technology, Pharmaceuticals and Specialty Pharmaceuticals. It also provides opportunities for one-on-one meetings with investors and company-to-company meetings for commercial and strategic opportunities.

Merrion's presentation will be delivered by John Lynch, CEO, Merrion Pharmaceuticals.

According to John Lynch, CEO, Merrion Pharmaceuticals, the event presents the company with a compelling platform from which to showcase its new technologies and licensing successes and also to explore new opportunities going forward.

"Merrion Pharmaceuticals is at a point of development where we have an innovative but proven technology; a strong, well-respected partner-base and world-class scientific and executive teams. As such, events like the UBS Global Life Sciences Conference reflect well on our company and our prospects, but also enable us to connect with new partners in finance and industry," Lynch said today.


About UBS
Headquartered in Zurich and Basel, UBS is a client-focused financial services firm that offers a combination of wealth management, asset management and investment banking services on a global and regional basis. By delivering a full range of advice, products and services to our private, corporate and institutional clients, we aim to generate sustainable earnings, create value for our shareholders and be economically profitable in every segment, market and business in which we operate. Under Swiss company law, UBS is organized as an Aktiengesellschaft, a corporation that has issued shares of common stock to investors. UBS AG is the parent company of the UBS Group (Group). The operational structure of the Group comprises the Corporate Centre and four business divisions: Wealth Management & Swiss Bank, Wealth Management Americas, Global Asset Management and the Investment Bank. UBS is present in all major financial centres and has offices in over 50 countries. It employs about 64,000 people around the world.

For further information see
http://www.ibb.ubs.com/conferences/americas/glsc2010invitationattendee/
index.html

About Merrion
Merrion Pharmaceuticals is a publicly listed product development company focused on
delivering innovation to the market by:

  • designing our own patented products and

• partnering with other pharmaceutical companies to develop patented products.

 

Established in 2003, Merrion are engaged in the development of oral forms
(tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion Pharmaceutical's patented drug delivery technologies (GIPET®) hugely increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. As well as increasing absorption, Merrion's technologies also increase the consistency of absorption. These new products can provide substantial benefits in enhanced drug efficacy, improved safety, toxicity and side effect profile, health economics, patient experience and quality of life. Merrion has agreements with several pharmaceutical companies. Merrion has two license agreements with Novo Nordisk A/S to develop and commercialise oral Insulin and oral GLP-1 using Merrion's GIPET technology. Merrion also has an oral drug delivery research collaborative program with Ferring Pharmaceuticals, a Swiss based international pharmaceutical company. There are other, unannounced collaborations.
Merrion Pharmaceuticals is based in Dublin, in a state of the art, purpose built cGMP facility which allows rapid development and reduced risk in taking product ideas from conception to final product formulation. Merrion also has operations in Wilmington, North Carolina.
Merrion is listed on the Irish Stock Exchange (ESM) under the symbol MERR

###

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.